共同药业
(300966)
| 流通市值：17.11亿 | | | 总市值：25.75亿 |
| 流通股本：7658.01万 | | | 总股本：1.15亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 346,273,021.22 | 161,937,521.77 | 606,178,267.31 | 455,071,340.26 |
| 营业总成本 | 390,450,162.97 | 163,784,967.65 | 708,683,380.01 | 505,144,105.05 |
| 其他经营收益 | | | | |
| 营业利润 | -37,610,381.03 | -1,287,926.03 | -100,985,005.67 | -52,441,061.48 |
| 利润总额 | -38,207,246.12 | -1,277,717.82 | -105,214,803.97 | -53,658,033.91 |
| 净利润 | -38,353,335.12 | 1,122,583.06 | -81,726,282.34 | -37,430,322.36 |
| 每股收益 | | | | |
| 其他综合收益 | - | 0 | - | - |
| 综合收益总额 | -38,353,335.12 | 1,122,583.06 | -81,726,282.34 | -37,430,322.36 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 837,263,385.13 | 825,170,510.54 | 770,287,408.19 | 779,686,448.17 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,066,587,207.2 | 2,070,951,176.33 | 2,080,370,851.02 | 2,077,076,297.23 |
| 资产总计 | 2,903,850,592.33 | 2,896,121,686.87 | 2,850,658,259.21 | 2,856,762,745.4 |
| 流动负债: | | | | |
| 流动负债合计 | 902,366,747.46 | 833,211,748 | 822,076,779.57 | 762,840,757.28 |
| 非流动负债: | | | | |
| 非流动负债合计 | 1,129,237,853.44 | 1,152,301,282.89 | 1,119,224,533.76 | 1,136,016,467.93 |
| 负债合计 | 2,031,604,600.9 | 1,985,513,030.89 | 1,941,301,313.33 | 1,898,857,225.21 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 794,565,118.67 | 829,547,390.29 | 826,219,731.57 | 871,396,588.82 |
| 股东权益合计 | 872,245,991.43 | 910,608,655.98 | 909,356,945.88 | 957,905,520.19 |
| 负债和股东权益合计 | 2,903,850,592.33 | 2,896,121,686.87 | 2,850,658,259.21 | 2,856,762,745.4 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 247,416,915.76 | 100,396,109.21 | 587,686,880.95 | 412,169,849.05 |
| 经营活动现金流出小计 | 224,941,055.95 | 100,294,235.11 | 546,650,490.62 | 418,335,857.41 |
| 经营活动产生的现金流量净额 | 22,475,859.81 | 101,874.1 | 41,036,390.33 | -6,166,008.36 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 26,237 | 2,832 | 183,709 | 133,709 |
| 投资活动现金流出小计 | 35,471,999.09 | 26,054,569.82 | 166,326,364.17 | 141,243,927.94 |
| 投资活动产生的现金流量净额 | -35,445,762.09 | -26,051,737.82 | -166,142,655.17 | -141,110,218.94 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 174,339,373.23 | 110,000,000 | 468,380,787.85 | 413,800,628.84 |
| 筹资活动现金流出小计 | 174,071,558.48 | 98,292,027.56 | 378,195,138.34 | 285,227,544.88 |
| 筹资活动产生的现金流量净额 | 267,814.75 | 11,707,972.44 | 90,185,649.51 | 128,573,083.96 |
| 汇率变动对现金及现金等价物的影响 | -230,900.89 | 2.94 | -64,040.56 | -43,987.36 |
| 现金及现金等价物净增加额 | -12,932,988.42 | -14,241,888.34 | -34,984,655.89 | -18,747,130.7 |
| 期末现金及现金等价物余额 | 52,204,388.71 | 50,895,488.79 | 65,137,377.13 | 81,374,902.32 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -12,932,988.42 | - | -34,984,655.89 | - |